Differences and diversity of autoimmune-mediated encephalitis in 77 cases from a single tertiary care center

CURRENT STATUS: ACCEPTED

Abhinbhen Wasontiwong Saraya  abhinbhen@gmail.com
Chulalongkorn University Faculty of Medicine
Corresponding Author
ORCiD: 0000-0002-0579-5960

Kanthita Worachotsueptrakun
Thai Red Cross Emerging Infectious Disease Health Science Center

Kritchai Vutipongsatorn
Thai Red Cross Emerging Infectious Disease Health Science Center

Chanikarn Sonpee
Thai Red Cross Emerging Infectious Disease Health Science Center

Thiravat Hemachudha
Chulalongkorn University Faculty of Medicine

DOI:
10.21203/rs.2.1811/v3

SUBJECT AREAS
Internal Medicine Specialties

KEYWORDS
encephalitis, autoimmune encephalitis, paraneoplastic encephalitis, limbic encephalitis
Abstract

Background The incidence of autoimmune encephalitis has risen globally. There are two general categories of disease-associated antibodies that can be tested for: neuronal surface and intracellular. However, testing both groups of autoantibodies are costly. This study aims to identify differences between groups by comparing clinical presentations, radiological findings and CSF profile of patients, and determine if any parameters are indicative of one group of autoantibodies over another. Additionally, we aim to report the local incidence of less common groups of disease-associated antibodies as well. Methods 77 records of autoimmune encephalitis/encephalomyelitis patients admitted to King Chulalongkorn Memorial Hospital, Bangkok, Thailand, between October 2010 and February 2017 were reviewed. Patients with infections or those with classic central nervous system demyelinating features were excluded. Results Of 77 patients, 40% presented with neuronal surface antibodies and 33% had intracellular antibodies. The most common autoantibody detected in each group was anti-NMDAr antibody (25/31, 81%) and anti-Ri antibody (7/25, 28%) respectively. In the neuronal surface antibody group, behavioral change was the most common complaint (45%), followed by seizures (39%) and abnormal movements (29%). In the latter group, seizure was the most common presenting symptom (32%), followed by motor weakness (20%), behavioural change (16%) and abnormal movements (16%). Patients with neuronal surface antibodies were younger (35 vs 48 years old, p=0.04) and more likely to present with behavioral change (45% vs 16%, p=0.02). Mortality rate was higher in the intracellular group (16% vs 3.2%, p=0.09). No differences were detected in magnetic resonance imaging (MRI) and CSF profile. Conclusions In the early stages of the disease, both groups have comparable clinical outcomes. Although there were significant differences in age and percentage of patients with behavioral change, both groups of autoimmune encephalitis still shared many clinical
features and could not be distinguished based on MRI and CSF profiles. Therefore, we recommend that patients with features of autoimmune encephalitis should be screened for both the neuronal surface and intracellular antibodies regardless of clinical presentation.

**Background**

Autoimmunity is a major cause of encephalitis. It is now as common as infectious etiology. Since the discovery of N-methyl-D-aspartate receptor (NMDAr) antibody by Dalmau et al. in 2007 (1), the incidence of autoimmune encephalitis has been rising globally from 0.4/100,000 person-year (1995–2005) to 1.2/100,000 person-year (2006–2015) (2-7).

Additionally, with several novel neuronal antibodies discovered recently such as LGI1, CASPR2, GABA-A/Br, anti-dopamine2 receptor, anti-DPPX, anti-IgLON5 and neurexin-3α (8-15), it is plausible that the diagnosis of autoimmune encephalitis will continue to rise. Antibodies responsible for autoimmune encephalitis are broadly classified into two categories: neuronal surface and intracellular antibodies (16). The neuronal surface group comprises of antibodies to surface receptors and protein complexes such as NMDAr, AMPAr, CASPR2, LGI-1 and GABAr (17, 18). On the other hand, the intracellular group (classic paraneoplastic antibodies), consists of antibodies against intracellular antigens (e.g., Hu, Ri, Yo and CV2) (19).

Several methods can be used to identify these autoantibodies in the serum and cerebrospinal fluid (CSF). In autoimmune encephalitis, techniques such as immunoblotting, immunohistochemistry, and immunocytochemistry with immunofluorescence assays are most commonly used (20). However, these assays are time-consuming and costly especially if several panels of autoantibodies are tested. Therefore, by comparing the clinical data, radiological results and CSF profiles of patients, we hope to identify key differences that will determine which set of autoantibodies patients are likely to have in order to eliminate unnecessary tests. This would free up time
and resources that can be spent on other aspects of healthcare. Additionally, the results could be applicable to other developing countries who could benefit from this cost-saving strategy. Furthermore, this study also aims to report the local incidence and clinical presentations of other less common disease-associated antibodies groups.

Methods

Participants

77 records of patients with autoimmune encephalitis/encephalomyelitis admitted to KCMH between October 2010 and February 2017 were reviewed. The study has been approved by the Ethics Committee of the Faculty of Medicine, Chulalongkorn University and KCMH (IRB number 329/60).

Selection Criteria

Patients with infectious encephalitis and those with classical demyelinating features were excluded from this study. Patients were included if they met the criteria for encephalitis, which is one or more of the following presentations (21): cognitive disturbance, behavioral change, focal neurological abnormalities and seizures plus the detection of well-defined antibodies against cell-surface, synaptic, or intracellular proteins in serum or CSF.

According to the criteria proposed by Graus et al., antibody negative autoimmune encephalitis was diagnosed in patients who had rapid progression of working memory deficits, altered mental status, or psychiatric symptoms and absence of well-characterized autoantibodies in serum and CSF (22). The diagnosis of neuro-psychiatric lupus erythematosus (NPLE) was initially determined by clinical assessment, followed by positive results of either ANA, anti-ribosomal P, anti-cardiolipin or lupus anticoagulant in serum (23). The diagnosis of Hashimoto’s encephalitis comprised of encephalopathy with seizures, myoclonus, hallucinations or stroke-like episodes and subclinical or mild overt thyroid disease with positive serum thyroid antibodies (22). We used the descriptions of
psychopathological features according to Al-Diwani et al. (24) in our study. “Behavior” included agitation, aggression, disorganisation, incoherent speech, violence, incongruent laughter/crying, disinhibition, hyper-religiosity, impulsivity and talking to self. Catatonia referred to mutism, stupor, verbigeration and waxy flexibility.

**Investigations**

Routine laboratory results were reviewed. These included complete blood count, blood urea nitrogen, creatinine, serum electrolytes, HIV antibody, chest x-ray and liver function tests. Blood cultures were performed in every febrile case. Serum and/or CSF were also collected for autoantibody screening. Autoantibodies panel tests were routinely used in the suspected cases since 2014. The specimens from 2010-2013 were also retrospectively tested and reported (2). Indirect immunofluorescence (IIF) autoimmune panel consisted of anti-NMDAr, anti-AMPAR-1 and 2, anti-CASPR2, anti-LGI-1, anti-GABAr-A and B and DPPX (EUROIMMUN®). The IIF paraneoplastic (PNS) panels and immunoblot anti-neuronal IgG profile comprised of anti-Hu (ANNA-1), anti-Ri (ANNA-2), anti-Yo (PCA-1), PCA-2, anti-Tr, anti-MAG, anti-myelin, anti-GAD, anti-CV2, anti-PNMA2, anti-ampiphysin, anti-neuroendothelium, anti-GFAP, anti-synaptophysin and AGNA/anti-SOX1 (EUROIMMUN®). After collection, the sample was diluted 10-fold and incubated for 30 minutes at room temperature on slides containing either specific antigen-expressing HEK cells or tissues that naturally expressed these antigens (e.g., cerebellum, pancreas, intestine and nerve cell). They were then incubated in secondary antibody conjugated with fit-C fluorescence and observed under an inverted fluorescence microscope. As for the immunoblot assay (EUROLINE®), specimen was diluted accordingly (1:101 for anti-neuronal) put on the test strip and incubated for 30-120 minutes. After a wash, the strip was incubated with conjugated enzyme and substrate before being evaluated by EUROLineScan®. The IIF assay for aquaporin-4 (AQP4) antibody, anti-thyroid peroxidase and anti-thyroglobulin was
also conducted in some cases based on clinical suspicion.  

All patients were screened for tumor by computed tomography (CT) of chest and whole abdomen including pelvis. Pelvic examination and ultrasonography were performed in female patients with anti-NMDAr and anti-Yo. Mammogram was also indicated in some cases based on clinical judgement. Modified Rankin Scale (mRS) was used to evaluate patients before discharge.  

**Statistics**  

SPSS software version 17 was used to describe and compare epidemiological data between neuronal surface and intracellular groups. Categorical data were analyzed using chi-square and Fisher’s exact test. Mann-Whitney U test was performed to analyze numerical data. *P*-value of less than 0.05 was considered statistically significant.  

**Results**  

77 patients in this study were from 24 provinces nationwide with 50 cases from the central region of Thailand. 31 cases (40.3%) presented with neuronal surface antibodies while 25 cases (32.5%) had intracellular antibodies. 28% of patients belonged to the systemic autoimmune diseases (NPLE and Hashimoto’s encephalopathy), coexisting neuronal antibodies, antibody-negative autoimmune encephalitis, infection-related neuronal antibody positive group (syphilis and listeria monocytogenes infections) and atypical AQP4-IgG, which presented with encephalitis syndrome (Figure 1). The prevalence and characteristics of autoantibodies from each group of autoimmune encephalitis are described in Figure 1 and Table 1.  

Table 1: Description of autoantibodies seen in neuronal surface antibody group, intracellular antibody group and coexisting-antibodies group

| Antibodies | Number of serum | Number of CSF | Age range | % Male | Presenting symptoms |
|------------|-----------------|---------------|-----------|--------|---------------------|
|            |                 |               |           |        |                     |
| Antibody | Positive Patients | (Year) | Presentation |
|----------|------------------|--------|--------------|
| Anti-NMDAr (25 cases) | 24 (8 N/A) | 5-79 | 44.1 | Behavior, psychosis, dyskinesia, seizures, memory impairment, catatonia, mood disorders |
| Anti-AMPAr (2 cases) | 2 (1 N/A) | 2-72 | 50.0 | Behavior, stiff-person syndrome |
| Anti-GABA-Br (2 cases) | 2 (1 N/A) | 42-70 | 50.0 | Behavior, seizures, myoclonus |
| Anti-LGI1 (2 cases) | 2 (1 N/A) | 67-75 | 50.0 | Behavior, seizures, FBDS |
| Anti-Ri (ANNA2) (7 cases) | 7 (6 N/A) | 44-82 | 42.9 | Seizures, psychosis, dyskinesia, weakness |
| Anti-Yo (PCA1) (3 cases) | 3 (2 N/A) | 11-31 | 66.7 | Seizures, diplopia, drowsiness, weakness |
| Anti-PNMA2 (3 cases) | 3 (1 N/A) | 35-80 | 66.7 | Behavior, dyskinesia, rapidly progressive dementia, weakness |
| Anti-recoverin (3 cases) | 3 | 0 | 40-71 | 66.7 | Behavior, ataxia, numbness |
| Anti-CV2 (CRMP5) (2 cases) | 2 (1 N/A) | 59-65 | 50.0 | Psychosis, memory impairment |
| Anti-Hu antibody (2 cases) | 2 | N/A | 28-29 | 0.0 | Behavior, seizures, weakness, numbness |
| Anti-GAD65 (2 cases) | 2 (1 N/A) | 1-16 | 50.0 | Seizures, opsoclonus-myoclonus, ataxia |
| Anti-SOX1 (2 cases) | 2 | 2 | 33-66 | 50.0 | Behavior, dyskinesia |
| Anti-titin (1 case) | 1 | 0 | 86 | 0:0 | Drowsiness, psychomotor retardation |
| Anti-NMDAr +ANA (2 cases) | 2 | 2 | 15-30 | 0:0 | Behavior, psychosis, seizures |
| Anti-NMDAr +anti-Ri (1 case) | 1 | N/A | 18 | 100.0 | Seizures |
| Anti-NMDAr +AQP4 (1 case) | 1 | 1 | 24 | 0.0 | Behavior, dyskinesia, weakness |

NSCLC = non-small cell lung cancer  
FBDS = fasciobrachial dystonic seizure  
N/A = data not available

**Neuronal Surface Antibody Group**

Anti-NMDAr antibody is the most common antibody in the neuronal surface group (25/31 cases, 81%). Most patients (28 cases, 90.3%) had encephalitis with two and one cases of myelitis and encephalomyelitis respectively. The median age and range are shown in Table 2. Half of this group (16 cases, 51.6%) had no underlying diseases. Four patients were previously diagnosed with anti-NMDAr encephalitis with median recurrent time of 287.5 days (ranged from 61-456 days). One patient had HIV infections with CD4 count less than 200 cells/mm.³ A quarter of the patients (8 cases, 25.8%) also presented with prodromal symptoms such as headache and/or fever. However, they were absent in the remaining patients (23 cases, 74.2%).

Behavioral change was the most common presenting complaint with 14 cases (45.2%), followed by seizures (12 cases, 38.7%) and abnormal movements (9 cases, 29.0%) (Table 2). Among the nine patients with abnormal movements, five had chorea/dyskinesia (all
had anti-NMDAr with one patient also presented with catatonia), two had faciobrachial
dystonic seizures (both had anti-LGI1), one had stiff-person syndrome (anti-AMPAr-2), and
one had myoclonus (anti-GABAr).

CSF examination was obtained from 27 patients in this group. There were ten cases of
CSF pleocytosis (37.0%) and all had CSF white cell count below 100 cells/mm³. Most of
the remaining cases had normal CSF protein and glucose level. Only one patient (anti-
NMDAr) had a high CSF protein level of 242 mg/dl. Neuroimaging data were available in
27 cases. The majority presented with normal and non-specific findings (17 cases, 63.0%).
The most common abnormality in brain MRI was increased signal intensity in T2-weighted
image at the temporal lobe (3 cases, 11.1%). Other findings were leptomeningeal
enhancement, subcortical, basal ganglia and multifocal lesions. In the neuronal surface
antibody group, three cases of tumor (9.7%) were found on admission or during the first
follow-up (Table 1).

14 patients (45.2%) received immunotherapy (IVIg 2g/kg/course or plasmapheresis 5
cycles) and 18 patients (58.1%) were given intravenous methyl prednisolone 1g/kg/day for
5 days. Tumors were appropriately treated upon discovery. Median length of stay in the
hospital was 24 days (ranged from 4-150 days). Seven patients (22.6%) had poor outcome
at discharge from hospital (mRS score 4-5) and one died from hospital acquired infection.

**Intracellular Antibody Group**

Anti-Ri was the most common autoantibody detected in the intracellular antibody group
(7/25 cases, 28%). Eleven (44.0%) had no underlying disease, four had SLE, one had
chronic HIV infections and one was previously diagnosed with malignant tumor (germ cell
tumor).

As seen in Table 2, seizure was the most common presenting symptom (8 cases, 32.0%),
followed by motor weakness (5 cases, 20.0%) and behavioral change (4 cases, 16.0%).
There were four cases (16.0%) of abnormal movements: one opsoclonus-myoclonus (anti-GAD65) and three generalized chorea (anti-Ri and anti-Sox1). Memory impairment was the first presenting complaint in two patients (8.0%). Six patients (24.0%) had tumors or evidence of malignancy with two patients presented with high blood level of CA-125 (anti-Yo, PNMA2) and the other four patients each presented with germ cell tumor (anti-Yo), ovarian tumor (anti-CV2), neuroblastoma (anti-GAD) and pancreatic cancer (PNMA2). Neuroimaging data were available in 22 patients. Nine (40.9%) had normal or non-specific lesions. Predominantly increased signal intensity lesions in a T2-weighted image and FLAIR image at medial temporal lobe was found in three patients (13.6%). Other lesions were found in the cerebral cortex, subcortical white matter, basal ganglia, thalamus, brainstem and cerebellum. CSF examination was performed on 21 patients. Five (23.8%) had a white blood cell count of more than 5 cells/mm$^3$, fifteen (71.4%) had a protein level of less than 100mg/dl and all had a normal glucose level.

Eight patients (32.0%) received IVIg 2g/kg/course and seven (28.0%) were given IV methyl prednisolone 1mg/kg/day for 5 days. Median length of stay in the hospital was 31 days (range 5-126). Six patients (24.0%) had poor outcome at discharge from hospital (mRS score 4-5) and four (16.0%) died. The causes of death were hospital acquired pneumonia (2 cases) and septicemia (2 cases).

**Systemic Autoimmune Encephalitis Group**

There were nine cases in the systemic autoimmune encephalitis group with six resulted from neuropsychiatric lupus erythematosus (NPLE). The median age of patients in this group was 33 (range 17-67) and most of the cases were female (88.9%). Four patients had been diagnosed with SLE prior to admission and two had underlying thyroid disease. Two cases presented with myelitis, while the remaining seven had encephalitis symptoms such as behavioral changes, seizure, psychosis, memory impairment and altered
consciousness. Most patients in this group had normocellular CSF with normal CSF glucose level. Only three cases had a CSF protein level of over 60mg/dl. Six patients underwent brain MRI and half of them presented with normal or non-specific findings. Others showed increased signal intensity lesions in a T2-weighted image and FLAIR image at the cortical area, subcortical white matter and midline structures. No evidence of tumor was detected in this group. A large proportion of patients (44.4%) received high dose corticosteroids for treatment with a median hospital stay of 20 days. In terms of outcome at discharge from hospital, four patients partially recovered while the other four became disabled. One patient with NPLE had died.

**Mixed Autoantibodies Group**

There were four cases of mixed autoantibodies with all four presented with anti-NMDAr antibody and one additional autoantibody (Table1). Neuropsychiatric lupus was diagnosed in two patients who both had systemic SLE and ANA level of 1:2560. They also presented with behavioral change and psychosis. Neuroimaging was unremarkable except for the patient with coexisting NMO antibody who had lesions at the midline and cortical structures.

Table 2: Comparison between neuronal surface antibody group and intracellular antibody group

mRS = modified Rankin Scale
| Characteristics          | Neuronal surface antibodies (n = 31) | Intracellular antibodies (n = 25) |
|-------------------------|-------------------------------------|-----------------------------------|
| Baseline Gender         |                                     |                                   |
| - male                  | 14 (45.2%)                          | 12 (48%)                          |
| - female                | 17 (54.8%)                          | 13 (52%)                          |
| median age (years)      | 30.5 (2-79)                         | 45.5 (1-86)                       |
| Presenting symptoms     |                                     |                                   |
| Behavior                | 14 (45.2%)                          | 4 (16%)                           |
| Psychosis/mood          | 7 (22.6%)                           | 3 (12%)                           |
| Seizures                | 12 (38.7%)                          | 8 (32%)                           |
| Abnormal movements (total) | 12 (38.7%)                     | 6 (24%)                           |
| Generalized dyskinesia/chorea | 5 (16.1%)                  | 3 (12%)                           |
| CSF profile             |                                     |                                   |
| median CSF white blood cell (cells/mm³) | 2 (0-82)                     | 1 (0-31)                           |
| median CSF protein (mg/dl) | 26.5 (11-242)                         | 44 (2-440)                         |
| median CSF glucose (mg%) | 65.5 (44-149)                        | 67 (42-95)                         |
| Duration of disease onset to treatment(days) | 15 (1-420)                     | 20 (1-700)                         |
| Median hospital stay (days) | 23 (4-150)                      | 31.5 (5-126)                       |
| Outcome at discharge from hospital |                                     |                                   |
| Completely recovered (mRS 0-1) | 3 (9.7%)                 | 0 (0%)                             |
| Partially recovered (mRS 2-3) | 20 (64.5%)                     | 15 (60%)                           |
| Disable (mRS 4-5)       | 7 (22.6%)                           | 6 (24%)                           |
| Dead                    | 1 (3.2%)                            | 4 (16%)                           |

**Discussion**

**Comparison Between Local Population and Other Studies**

This study described the clinical, radiological and laboratory findings in patients with autoimmune encephalitis diagnosed and treated at a tertiary care hospital in Bangkok, Thailand. Antibodies against neuronal surface antigen were the most common followed by those against intracellular antigen (46% and 38%, respectively). The most common autoimmune encephalitis in this study was anti-NMDAr encephalitis. This is consistent with other studies, which report that anti-NMDAr encephalitis is the most prevalent immune-
mediated encephalitis worldwide to date (25, 26). Some reports found that anti-LGI1 was presumed to be the second most common cause of autoimmune encephalitis among the neuronal surface antibodies group (12, 27). However, we only identified two cases of anti-LGI1 encephalitis among 31 cases (6%). This is likely because LGI1 antibodies were more common among elderly patients with antibody-associated central nervous system (CNS) syndrome (28, 29), while the majority of patients in our study were middle-aged (mean age of 40). Both cases of anti-LGI1 encephalitis in our study had FBDS that responded to immunotherapy rather than anti-epileptic drugs, which is similarly reported by Thompson et al. (30). Additionally, these two patients were more than 50 years old and only had CNS manifestations—a finding that is consistent with Gadoth et al. (31).

Among the two cases of anti-AMPAr antibody encephalitis, one had SCLC, which was the most commonly associated tumor (32). The other patient, a 2-year-old girl with no malignancy detected, presented with a stiff-person syndrome. She eventually recovered after receiving baclofen and supportive treatment. Her serum anti-AMPAr antibody was subsequently negative at a 3-month-follow up.

There are some differences in this study and previously published literature. For instance, in the neuronal surface group, only 26% of our cohort had presented with prodromal symptoms while some studies have suggested that this figure could be as high as 61-70% (25, 33, 34). Additionally, CSF pleocytosis was detected in 37% of our patients compared to 80% in a previous review (33).

There was a strong association between anti-NMDAr encephalitis and ovarian tumor/teratoma (1, 35, 36), especially among Asian and African-American women where 50% of adult female patients were estimated to have ovarian teratoma (37). However, in our study, only two cases (9%) of ovarian tumor were found at the first immediate tumor screening despite a thorough investigation with abdominal and pelvic CT and pelvic
ultrasonography. Interestingly, this is consistent with anti-NMDAr encephalitis case series in China (25) and Korea (38), which found that ovarian tumor was present in four (8%) and two (9%) patients respectively. However, since paraneoplastic neurological syndromes can present within five years of the initial diagnosis (39), annual tumor screening should be performed in the remaining cases. Furthermore, oro-facial dyskinesia was the most common movement disorder among anti-NMDAr encephalitis patients in our study, which is consistent with previous studies (26, 35, 40). However, we did not find dystonia as common as suggested by Varley et al. (41) and there was only one case of catatonia in our study.

There were three patients (4%) that fit the criteria of autoantibody negative autoimmune encephalitis. This raises a question of whether there is truly no antibody or if there is an unknown neuronal antibody that we could not detect with the current tests used in our study.

Finally, we discovered that some patients had non-classical paraneoplastic autoantibodies such as anti-recoverin, anti-titin and anti-SOX1, which were usually not considered as the cause of paraneoplastic CNS disease. Anti-recoverin is one of the causes of cancer-associated retinopathy (42). Here, we found three cases of anti-recoverin associated encephalitis that presented with behavioral symptoms. Anti-titin and anti-SOX1 often present with other classical paraneoplastic antibodies (anti-Hu, Ri, Yo etc.) in paraneoplastic syndrome of the nervous system (43, 44). Since no other coexisting autoantibodies were identified in our cases, these antibodies may be directly responsible for the neurological symptoms seen.

**Comparison Between Neuronal Surface and Intracellular Groups**

Since the majority of autoimmune encephalitis patients in our study belonged to either the neuronal surface group or the intracellular group, the differences between these two
groups were summarized in Table 2.

Patients in the intracellular group were significantly older than those in the neuronal surface group (48 vs. 35 years old, \( p = 0.04 \)). Furthermore, behavioral change, which was the third most common symptom in the intracellular group, was significantly more common in the neuronal surface group as well (45% vs. 16%, \( p = 0.02 \)). On the other hand, seizure was the most common complaint in the intracellular group, but there were no significant differences in its prevalence between the two groups (32% vs. 39%, \( p = 0.60 \)). Abnormal movements and psychiatric features were more common in neuronal surface group, but similarly there were no significant differences (\( p = 0.24 \) and 0.30 respectively). Additionally, the intracellular group tended to have a longer duration of symptoms before admission to hospital (3 months vs 2 months).

As for CSF profile, the intracellular group had a large proportion of normocellular CSF (76%). Neuroimaging (MRI) data could not distinguish between these two groups of autoantibody-mediated encephalitis.

The recovery rate and morbidity at discharge from hospital between both groups were comparable. The mortality rate was noticeably higher in the intracellular group although this was not statistically significant (16% vs. 3.2%, \( p = 0.16 \)). Therefore, it seems that at least in the early stages of the disease, patients with surface and intracellular antibodies have similar outcome. However, further studies with more participants and higher power are needed to confirm this result.

**Conclusion**

We described different groups of autoimmune encephalitis patients in Thailand. The two most prevalent groups were neuronal surface and intracellular groups, with the former being more common than the latter. However, in the earlier stages of the disease, both groups have comparable clinical outcomes. Even though the age of onset and percentage
of patients with behavioral change were statistically different between these two groups, they still shared many clinical features and could not be distinguished based on radiological findings and CSF profiles. As such, we recommend that patients with suspected autoimmune encephalitis should be screened for both the neuronal surface and intracellular antibodies.

**Abbreviations**

NMDAr (N-methyl-D-aspartate receptor), AMPAr (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor), CASPR2 (contactin-associated protein-like 2), LGI-1 (Leucine-rich glioma-inactivated 1), GABAr (gamma-aminobutyric acid receptor), DPPX (dipeptidyl-peptidase–like protein 6), ANNA (anti-neuronal nuclear antibody), PCA (Purkinje cell antibody), MAG (myelin-associated glycoprotein), GAD (glutamic acid decarboxylase), GFAP (Glial Fibrillary Acidic Protein), AGNA (antiglial nuclear antibodies), AQP-4 1 (Aquaporin-4), FBDS (faciobracial dystonic seizure), SCLC (small cell lung cancer), FLIAR (Fluid-attenuated inversion recovery).

**Declaration**

Ethics approval and consent to participate: Approval has been granted by the Ethics Committee of the Faculty of Medicine, Chulalongkorn University and KCMH, IRB number 329/60.

Consent for publication: Since the study was retrospective, the need for individual consent was waived by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Availability of data and material: Data used and/or analyzed in this study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests.
Funding: Ratchadapiseksompotch Fund (Faculty of Medicine, Chulalongkorn University, grant number RA61/013) was used to support data collection and statistical analysis of this study.

Authors' contributions: AS and KV reviewed the medical records. AS wrote the main manuscript, analyzed the statistics and prepared the tables and figure. KW and CS performed the autoantibody tests and analyzed the results. AS and TH discussed the results. AS, KV and TH revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements: We wish to thank Dr. Supaporn Wacharapleusadee and Ms. Panticha Katarila for their help in preparing and reviewing the laboratory results.

References

1. Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25-36.

2. Saraya A, Mahavihakanont A, Shuangshoti S, Sittidetboripat N, Deesudchit T, Callahan M, et al. Autoimmune causes of encephalitis syndrome in Thailand: prospective study of 103 patients. BMC Neurol. 2013;13:150.

3. Gable MS, Gavali S, Radner A, Tilley DH, Lee B, Dyner L, et al. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis. 2009;28(12):1421-9.

4. MBBS SA, Lim S-Y, Goh KJ, Lum LC, Tan CT. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A series of ten cases from a university hospital in Malaysia. Neurology Asia. 2011;16(3):241-6.

5. Dubey D, Pittcock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis.
6. Kaneko J, Kanazawa N, Tominaga N, Kaneko A, Suga H, Usui R, et al. Practical issues in measuring autoantibodies to neuronal cell-surface antigens in autoimmune neurological disorders: 190 cases. J Neurol Sci. 2018;390:26-32.

7. Kamble N, Netravathi M, Saini J, Mahadevan A, Yadav R, Nalini A, et al. Clinical and imaging characteristics of 16 patients with autoimmune neuronal synaptic encephalitis. Neurol India. 2015;63(5):687-96.

8. Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, Murphy TK, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012;135(Pt 11):3453-68.

9. Piepgras J, Holtje M, Michel K, Li Q, Otto C, Drenckhahn C, et al. Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons. Neurology. 2015;85(10):890-7.

10. Gaig C, Graus F, Compta Y, Hogl B, Bataller L, Bruggemann N, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88(18):1736-43.

11. Gresa-Arribas N, Planaguma J, Petit-Pedrol M, Kawachi I, Katada S, Glaser CA, et al. Human neurexin-3alpha antibodies associate with encephalitis and alter synapse development. Neurology. 2016;86(24):2235-42.

12. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734-48.

13. Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9(1):67-76.
14. Ohkawa T, Satake S, Yokoi N, Miyazaki Y, Ohshita T, Sobue G, et al. Identification and characterization of GABA(A) receptor autoantibodies in autoimmune encephalitis. J Neurosci. 2014;34(24):8151-63.

15. Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13(3):276-86.

16. Dalmau J, Graus F. Antibody-Mediated Encephalitis. N Engl J Med. 2018;378(9):840-51.

17. Dalmau J, Geis C, Graus F. Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev. 2017;97(2):839-87.

18. Planaguma J, Leypoldt F, Mannara F, Gutierrez-Cuesta J, Martin-Garcia E, Aguilar E, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015;138(Pt 1):94-109.

19. Lancaster E. Paraneoplastic Disorders. Continuum (Minneap Minn). 2017;23(6, Neuro-oncology):1653-79.

20. van Coevorden-Hameete MH, Titulaer MJ, Schreurs MW, de Graaff E, Sillevis Smitt PA, Hoogenraad CC. Detection and Characterization of Autoantibodies to Neuronal Cell-Surface Antigens in the Central Nervous System. Frontiers in molecular neuroscience. 2016;9:37.

21. Steiner I, Budka H, Chaudhuri A, Koskiniemi M, Sainio K, Salonen O, et al. Viral meningoencephalitis: a review of diagnostic methods and guidelines for management. Eur J Neurol. 2010;17(8):999-e57.

22. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach
23. Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10(6):338-47.

24. Al-Diwani A, Handel A, Townsend L, Pollak T, Leite MI, Harrison PJ, et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry. 2019;6(3):235-46.

25. Wang W, Li JM, Hu FY, Wang R, Hong Z, He L, et al. Anti-NMDA receptor encephalitis: clinical characteristics, predictors of outcome and the knowledge gap in southwest China. Eur J Neurol. 2016;23(3):621-9.

26. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63-74.

27. van Sonderen A, Petit-Pedrol M, Dalmau J, Titulaer MJ. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nature reviews Neurology. 2017;13(5):290-301.

28. Escudero D, Guasp M, Arino H, Gaig C, Martinez-Hernandez E, Dalmau J, et al. Antibody-associated CNS syndromes without signs of inflammation in the elderly. Neurology. 2017;89(14):1471-5.

29. Celicanin M, Blaabjerg M, Maersk-Moller C, Beniczky S, Marner L, Thomsen C, et al. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies - a national cohort study. Eur J Neurol. 2017;24(8):999-1005.

30. Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018;141(2):348-56.
31. Gadoth A, Pittock SJ, Dubey D, McKeon A, Britton JW, Schmeling JE, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol. 2017;82(1):79-92.

32. Dogan Onugoren M, Deurentzbacher D, Haensch CA, Hagedorn HJ, Halve S, Isenmann S, et al. Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry. 2015;86(9):965-72.

33. Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci. 2015;1338:94-114.

34. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005;58(4):594-604.

35. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-8.

36. Day GS, Laiq S, Tang-Wai DF, Munoz DG. Abnormal neurons in teratomas in NMDAR encephalitis. JAMA Neurol. 2014;71(6):717-24.

37. Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013.

38. Lim JA, Lee ST, Jung KH, Kim S, Shin JW, Moon J, et al. Anti-N-methyl-d-aspartate receptor encephalitis in Korea: clinical features, treatment, and outcome. J Clin Neurol. 2014;10(2):157-61.

39. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135-40.
40. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66(1):11-8.

41. Varley JA, Webb AJS, Balint B, Fung VSC, Sethi KD, Tijssen MAJ, et al. The Movement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: an expert video-rating study. J Neurol Neurosurg Psychiatry. 2018.

42. Shiraga S, Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol. 2002;132(1-2):72-82.

43. Stich O, Klages E, Bischler P, Jarius S, Rasiah C, Voltz R, et al. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes. Acta neurologica Scandinavica. 2012;125(5):326-31.

44. Berger B, Stich O, Labeit S, Rauer S. Screening for anti-titin antibodies in patients with various paraneoplastic neurological syndromes. J Neuroimmunol. 2016;295-296:18-20.

Figures
Figure 1

Proportion of each groups of autoimmune encephalitis